AstraZeneca Pharma India (BOM:506820) Interest Expense : ₹-12 Mil (TTM As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. AstraZeneca Pharma India's interest expense for the three months ended in Mar. 2024 was ₹ 1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-12 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. AstraZeneca Pharma India's Operating Income for the three months ended in Mar. 2024 was ₹ 456 Mil. AstraZeneca Pharma India's Interest Expense for the three months ended in Mar. 2024 was ₹ 1 Mil. AstraZeneca Pharma India did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AstraZeneca Pharma India Interest Expense Historical Data

The historical data trend for AstraZeneca Pharma India's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Pharma India Interest Expense Chart

AstraZeneca Pharma India Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-11.40

-10.90

-9.50

-6.33

-12.01

AstraZeneca Pharma India Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.88	-1.54	-5.00	-6.13	0.66

AstraZeneca Pharma India Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-12 Mil.

AstraZeneca Pharma India (BOM:506820) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AstraZeneca Pharma India's Interest Expense for the three months ended in Mar. 2024 was ₹1 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₹456 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₹28 Mil.

AstraZeneca Pharma India's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. AstraZeneca Pharma India Ltd has enough cash to cover all of its debt. Its financial situation is stable.

AstraZeneca Pharma India (BOM:506820) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (BOM:506820) » Definitions » Interest Expense

Traded in Other Exchanges

ASTRAZEN:India

Address

Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045

Website

https://www.astrazeneca.com

AstraZeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Its only operating segment being Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation and Autoimmunity, Neuroscience and Infection and Vaccines.

AstraZeneca Pharma India (BOM:506820) Headlines

No Headlines